Last reviewed · How we verify
Bleomycin Etoposide and Cisplatin
This combination chemotherapy regimen uses three agents that damage DNA and inhibit cell division to kill cancer cells.
This combination chemotherapy regimen uses three agents that damage DNA and inhibit cell division to kill cancer cells. Used for Germ cell tumors (testicular cancer), Lymphomas, Small cell lung cancer.
At a glance
| Generic name | Bleomycin Etoposide and Cisplatin |
|---|---|
| Also known as | BEP |
| Sponsor | St. Olavs Hospital |
| Drug class | Combination chemotherapy (bleomycin + etoposide + cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bleomycin causes DNA strand breaks and prevents DNA repair; etoposide inhibits topoisomerase II to prevent DNA unwinding and replication; cisplatin is a platinum-based alkylating agent that cross-links DNA. Together, these agents work synergistically to induce apoptosis in rapidly dividing cancer cells.
Approved indications
- Germ cell tumors (testicular cancer)
- Lymphomas
- Small cell lung cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Nephrotoxicity
- Ototoxicity
- Pulmonary toxicity (bleomycin-related)
- Peripheral neuropathy
Key clinical trials
- Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors (PHASE3)
- Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer (PHASE3)
- PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND (PHASE2)
- Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors (PHASE2)
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (PHASE3)
- Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors (NA)
- Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors (PHASE3)
- Prognostic Significance of ctDNA in HL
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bleomycin Etoposide and Cisplatin CI brief — competitive landscape report
- Bleomycin Etoposide and Cisplatin updates RSS · CI watch RSS
- St. Olavs Hospital portfolio CI